Treatment of influenza A (H1N1) virus infection with ribavirin aerosol | Zendy

S Z Wilson | Zendy; Brian E. Gilbert | Zendy; John M. Quarles | Zendy; Ver Knight | Zendy; HarveyW. Mcclung | Zendy; Rebecca V. Moore | Zendy; R. B. Couch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of influenza A (H1N1) virus infection with ribavirin aerosol

Author(s) -

S Z Wilson,

Brian E. Gilbert,

John M. Quarles,

Ver Knight,

HarveyW. Mcclung,

Rebecca V. Moore,

R. B. Couch

Publication year - 1984

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.26.2.200

Subject(s) - ribavirin , virus , medicine , viral shedding , influenza a virus , virology , gastroenterology , immunology , hepatitis c virus

In a randomized, controlled study of ribavirin aerosol treatment of influenza A(H1N1) virus infection among college students, treated patients had a significantly shorter duration of fever than control patients. There was a trend of more rapid recovery in treated patients. Virus shedding was similar in treated and control patients, declining gradually from a 50% tissue culture infective dose of 3.5 log10 per ml at admission to 1.8 log10 per ml at 53 h after admission. There was no local or systemic intolerance and no hematological or biochemical abnormalities associated with ribavirin treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research